Furthermore, ISIM-treated mice contained more circulating CD8+ T cells expressing 4-1BB and CX3CR1, a marker of effector differentiation26,27 (Supplementary Fig. 7c), and these markers were preferentially expressed in Tet+ CD8+ T cells in 4T1 tumor-bearing mice (Supplementary Fig. 7d). This evidence concerns the gene CD8A and neoplasm.